265 related articles for article (PubMed ID: 27395403)
21. Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.
Brahm NC; McElwain DL; Brown RC
Am J Health Syst Pharm; 2007 Apr; 64(8):827-9. PubMed ID: 17420198
[TBL] [Abstract][Full Text] [Related]
22. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.
Hill AL; Sun B; McDonnell DP
Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):216-22. PubMed ID: 23428782
[TBL] [Abstract][Full Text] [Related]
23. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.
Pringsheim T; Lam D; Ching H; Patten S
Drug Saf; 2011 Aug; 34(8):651-68. PubMed ID: 21751826
[TBL] [Abstract][Full Text] [Related]
24. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews.
Ribeiro ELA; de Mendonça Lima T; Vieira MEB; Storpirtis S; Aguiar PM
Eur J Clin Pharmacol; 2018 Oct; 74(10):1215-1233. PubMed ID: 29905899
[TBL] [Abstract][Full Text] [Related]
26. Focus on aripiprazole: a review of its use in child and adolescent psychiatry.
Greenaway M; Elbe D
J Can Acad Child Adolesc Psychiatry; 2009 Aug; 18(3):250-60. PubMed ID: 19718428
[TBL] [Abstract][Full Text] [Related]
27. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
Inada T; Beasley CM; Tanaka Y; Walker DJ
Int Clin Psychopharmacol; 2003 Jan; 18(1):39-48. PubMed ID: 12490774
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms.
Murphy JE; Stewart RB
Am J Hosp Pharm; 1979 May; 36(5):641-4. PubMed ID: 36755
[TBL] [Abstract][Full Text] [Related]
29. CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis.
Rudå D; Jensen KG; Decara MS; Klauber DG; Fagerlund B; Møllegaard JR; Linnet K; Werge T; Correll CU; Fink-Jensen A; Jürgens G; Pagsberg AK
J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):667-672. PubMed ID: 34735099
[TBL] [Abstract][Full Text] [Related]
30. Movement disorders associated with neuroleptic treatment.
Wirshing WC
J Clin Psychiatry; 2001; 62 Suppl 21():15-8. PubMed ID: 11584982
[TBL] [Abstract][Full Text] [Related]
31. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy.
Hong IS; Bishop JR
Ann Pharmacother; 2010; 44(7-8):1171-80. PubMed ID: 20587746
[TBL] [Abstract][Full Text] [Related]
32. The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao Extrapyramidal Syndromes Study II.
van Harten PN; Hoek HW; Matroos GE; Koeter M; Kahn RS
Schizophr Res; 1997 Aug; 26(2-3):235-42. PubMed ID: 9323356
[TBL] [Abstract][Full Text] [Related]
33. Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis.
Zheng W; Li XB; Xiang YQ; Zhong BL; Chiu HF; Ungvari GS; Ng CH; Lok GK; Xiang YT
Hum Psychopharmacol; 2016 Jan; 31(1):11-8. PubMed ID: 26310194
[TBL] [Abstract][Full Text] [Related]
34. Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.
Pierre JM
Drug Saf; 2005; 28(3):191-208. PubMed ID: 15733025
[TBL] [Abstract][Full Text] [Related]
35. Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders.
Gupta S; Masand P
Ann Clin Psychiatry; 2004; 16(3):155-66. PubMed ID: 15517848
[TBL] [Abstract][Full Text] [Related]
36. Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial.
Hsu JH; Mulsant BH; Lenze EJ; Sanches M; Karp JF; Reynolds CF; Blumberger DM
J Clin Psychiatry; 2018 Jun; 79(4):. PubMed ID: 29924506
[TBL] [Abstract][Full Text] [Related]
37. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs.
Peluso MJ; Lewis SW; Barnes TR; Jones PB
Br J Psychiatry; 2012 May; 200(5):387-92. PubMed ID: 22442101
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
39. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
